



Cite this: *Chem. Commun.*, 2025, 61, 8083

Received 3rd March 2025,  
Accepted 26th April 2025

DOI: 10.1039/d5cc01085c

rsc.li/chemcomm

**This work presents a late-stage aqueous peptide lipidation strategy via the thiol-Michael addition of thiolated lipids at dehydroalanine (Dha). This strategy was used to synthesise lipopeptides containing diacylglycerol (DAG), saturated, unsaturated and cholesterol lipid motifs. The DAG lipopeptide product was found to be a substrate for the lipoprotein processing enzyme, LspA.**

Lipidation is a ubiquitous co- and post-translational modification (PTM) of peptides and proteins that regulates numerous biological pathways, including cell signalling, membrane trafficking and protein secretion.<sup>1</sup> Typically, these lipids are fatty acyl or polyisoprenyl groups with modifications occurring at nucleophilic side chains, *e.g.*, cysteine, serine, and lysine, as well as the N-termini of peptides and proteins. Given the prevalence and functional importance of peptide and protein lipidation, the development of chemical methods that enable facile access to these bioconjugates is of critical importance for expanding our understanding of their biological function. Thus, the introduction of novel synthetic and semisynthetic lipidation methods remains a topic of intense investigation with several efficient strategies being reported to date.<sup>1–3</sup> These include in-line methods such as direct *N*- or *S*-lipidation during solid-phase peptide synthesis (SPPS),<sup>4,5</sup> as well as the incorporation of a pre-lipidated amino acid building block during SPPS.<sup>6</sup> Late-stage lipidation methods include direct alkylation,<sup>7</sup> Cu click,<sup>8</sup> thiol-ene click,<sup>9</sup> and enzymatic lipidation,<sup>10</sup> among others.<sup>11–13</sup>

DAG cysteine is a PTM found exclusively on bacterial lipoproteins with no eukaryotic orthologues.<sup>14</sup> Perhaps unsurprisingly, lipopeptides containing a DAG Cys (also known as Pam<sub>2</sub>Cys) are well-known toll-like receptor agonists and therefore appear in many self-adjuvanting vaccine candidates.<sup>15,16</sup> Synthetic lipopeptides displaying this DAG Cys motif have been


## Late-stage lipidation of peptides *via* aqueous thiol-michael addition to dehydroalanine (Dha)†

Glenna Swinand,<sup>a</sup> Matthew Rowe,<sup>a</sup> Katherine Bowen,<sup>a</sup> Samir Olatunji,<sup>b</sup> Martin Caffrey<sup>b</sup> and Eoin M. Scanlan<sup>a</sup>✉


used by our group and others as high-throughput probes for bacterial lipoprotein processing enzymes (Fig. 1B).<sup>17,18</sup> However, late-stage chemical lipidation methods for installing DAG lipid groups onto peptides or proteins have not previously been reported.

Dehydroalanine (Dha) is naturally occurring in some peptides, the most common examples of which are the lanthipeptides.<sup>19</sup> Dha is also frequently used as a reactive handle for peptide and protein modification in chemical synthesis. Following pioneering work by Davis and co-workers, Dha-mediated modification has been employed widely for the chemoselective installation of various functional groups onto peptides and proteins mimicking natural PTMs including glycosylation, phosphorylation, and lipidation (Fig. 1A).<sup>20,21</sup> Furthermore, Dha has been used to install reactive functional groups and tags onto proteins and peptides.<sup>22–24</sup> Dha is often generated *in situ* from a canonical amino acid and several methods for its formation have been reported.<sup>25</sup>

### A Previous Work in the Field



### B Previous Work in this Group



### C This Work




Fig. 1 Comparison of previous studies and this work.

<sup>a</sup> School of Chemistry, Trinity College Dublin, Trinity Biomedical Sciences Institute, Pearse St, Dublin 2, Ireland. E-mail: eoin.scanlan@tcd.ie

<sup>b</sup> School of Biochemistry and Immunology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Pearse St, Dublin 2, Ireland

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5cc01085c>




In this study, Dha is employed as a reactive intermediate under aqueous thiol-Michael addition conditions in a general approach to late-stage peptide lipidation (Fig. 1C). The strategy is applied to the synthesis of novel lipopeptides displaying DAG lipid motifs, including a Förster resonance energy transfer (FRET) probe. Chemical lipidation converts the peptide into a substrate for the bacterial enzyme lipoprotein signal peptidase II (LspA), highlighting the potential of this approach for the synthesis of functional peptides and proteins.

To begin our study, DAG thiol **4** was synthesised (Scheme 1). The initial two steps were informed by literature reports of a DAG Cys synthesis.<sup>17,18</sup> A base-mediated, nucleophilic epoxide ring opening reaction furnished diol **2**, followed by Steglich esterification with palmitic acid to furnish dipalmitoyl compound **3**. The thiol moiety was deprotected upon treatment with  $\text{BF}_3 \cdot \text{OEt}_2$  in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) as previously reported by Herczegh and co-workers.<sup>26</sup>

Next, optimisation studies of the thiol-Michael addition were performed using protected Dha amino acid **5** as a model system (Table 1). Inspired by the work of Boons and co-workers on the development of liposome-mediated native chemical ligation,<sup>27</sup> we included the detergent dodecylphosphocholine (DPC) in our reaction mixture to aid the poor aqueous solubility of the DAG group. The critical micelle concentration of DPC is  $\sim 1.1$  mM.<sup>28</sup> No product was formed in the absence of detergent (entry 1). When 1 equivalent of DAG thiol **4** was reacted with Dha amino acid **5** in the presence of DPC, a conversion of 95% to thioether **6** was determined after 18 h at rt (entry 2). Increasing the amount of thiol **4** to 2 equivalents resulted in a significant reduction in conversion however, this effect could be reversed by using a higher concentration of detergent, suggesting the potential disruption of micelle formation by the thiol when used in excess (entries 3 and 4). The reaction appeared tolerant of the higher concentration of detergent and this was maintained at 2.2 mM, even when the thiol concentration was reduced to 1.2 equivalents (entry 5).

This concentration was considered to be optimal and was retained for the remainder of Table 1. Next, the effects of varying pH were investigated with complete conversion of >99% observed under basic conditions (entry 7), whereas acidic conditions gave a reduced yield (entry 6). Basic conditions promote the formation of a more reactive thiolate and are well-known to catalyse thiol-Michael addition reactions.<sup>29</sup> Indeed, it was determined that

Table 1 Optimisation of thiol-Michael addition reaction conditions




Entry	Time (h)	Thiol (equiv.)	DPC conc (mM)	pH	% Yield <sup>a</sup>
1	4	1.5	0	7	0
2	18	1	1.1	7	95
3	18	2	1.1	7	54
4	18	2	2.2	7	80
5	18	1.2	2.2	7	82
6	18	1.2	2.2	4	69
7	18	1.2	2.2	9	> 99
8	1	1.2	2.2	9	86
9	3	1.2	2.2	9	98

<sup>a</sup> Yield determined by <sup>1</sup>H NMR spectroscopy.

86% and 98% conversion could be achieved in only 1 h and 3 h respectively, under basic conditions (entries 8 and 9). Anticipating potentially slower kinetics when this method was applied to more bulky peptide-based systems, we decided to proceed using the conditions which gave the highest yield overall (entry 7).

Using our optimised conditions (Table 1, entry 7), we next investigated a model peptide **7** with a series of lipid thiols (Fig. 2). The model peptide mimics the lipobox sequence in bacterial lipoproteins and can be found in activity probes for the bacterial lipoprotein processing enzyme, LspA.<sup>17</sup> Dha was formed *in situ* from the corresponding cysteine derivative to furnish peptide **7**, using conditions reported by Davis and co-workers (ESI†).<sup>25</sup> The crude peptide was used directly in the thiol-Michael addition without purification. All reactions were monitored by HPLC and % conversion was determined after 18 h (Fig. 2).

Three additional DAG lipid thiols **S1**, **S2** and **S3** were accessed *via* modification of the synthesis of **4** as outlined in Scheme 1. Thiol **S1** displays oleate esters, thiol **S2** displays a quencher moiety commonly used in combination with amino-benzoic acid (Abz) as a FRET pair, and thiol **S3** bears an alkyne functional group (Fig. S1, ESI†). Lipid thiols **S4** and **S5** were purchased from commercial suppliers and offer examples of both a simple monoalkyl chain lipid and a sterically challenging cholesterol derivative (Fig. S1, ESI†). Lipid thiol **S6** displays an acid-labile acetal-linked coumarin fluorophore inspired by a probe published by Shao and co-workers (Fig. S1, ESI†).<sup>30</sup> The highest conversions were achieved for lipopeptides **9**, **12** and **14**. The synthesis of lipopeptide **14** in high yield (>99%), with the retention of an acid-labile fluorescent tag, illustrates the advantage of the reported method over preparation by standard SPPS, which relies on a final acidic cleavage step. Good conversions were observed for **8** (79%), **10** (82%) and **11** (80%). This demonstrates a tolerance for the unnatural fluorophore structures in **10** and **14**, which are key for the development of high-throughput probes, and the alkyne click-chemistry handle on peptide **11**. Cholesterol derivative **13** reacted with lower conversion, likely due to the steric bulk and poor solubility of the



Scheme 1 Synthesis of DAG thiol **4**.






Fig. 2 Scope of lipopeptides synthesised using optimised conditions. Percentages are conversion of starting material to product measured by HPLC after 18 h.

substrate. As is common with addition reactions to Dha, no diastereoselectivity was observed in our reaction.<sup>31</sup> It was shown by <sup>1</sup>H NMR analysis of peptide **10** that the two diastereomers composing the lipopeptide product were present in a 1:1 ratio (ESI<sup>†</sup>). Importantly, these results demonstrate the broad scope of the methodology and its compatibility with saturated, unsaturated, and structurally complex lipids.

To further investigate the scope of this reaction, the method was applied to two additional model peptides to assess the feasibility of the reaction in the presence of other potentially reactive canonical amino acid side chains. Peptide **15** is inspired by the sequence found at the lipidation site of the drug liraglutide. Dha was once again formed *in situ* from cysteine with an increase in the reaction time from 5 h to 8 h required for conversion of Cys to Dha on both peptides **15** and **17** (ESI<sup>†</sup>). The crude peptides were reacted with decane thiol **S4** under the established conditions to furnish lipopeptides **16** and **18** in >99% conversion (Fig. 3). Glu underwent significant side reactions during the Dha-formation reaction when incorporated into a model peptide sequence. Thus Glu, Asp and Lys were also not used in the thiol-Michael addition reaction due to their nucleophilicity under basic conditions which could lead to inefficiency in the Dha-forming reaction step. These findings highlight the robustness of the method in the presence of the canonical amino acids.

To further validate this method, lipopeptide **10** was isolated and tested as a substrate and activity probe for the bacterial

lipoprotein processing enzyme, LspA. The natural function of LspA is to cleave a signal peptide from the N-terminus of lipidated bacterial proteins.<sup>14</sup> LspA cleaves the peptide bond between Cys and Gly in the highly conserved lipobox recognition sequence LAGC. Lipid **S2** contains the LAGC sequence, together with a dinitrophenyl group that creates a FRET pair with the Abz residue on the N-terminus of peptide **10**. Thus, as LspA cleaves the peptide bond between Cys and Gly, separating the FRET pair, the fluorescence of Abz increases. A similar FRET probe and the assay conditions were previously developed by our groups for a high-throughput drug discovery assay.<sup>17</sup> Lipopeptide **10** was evaluated as a substrate for LspA from *Pseudomonas aeruginosa* (LspPae). Using our established method, time course assays measuring the increase in fluorescence at 420 nm, characteristic of Abz, were run at a series of substrate concentrations (Fig. S2, ESI<sup>†</sup>). Thus, using a Michaelis-Menten kinetics model, the kinetic parameters  $V_{\max}$  and  $K_m$  for the enzymatic hydrolysis of peptide **10** by LspPae were determined to be 13.4 nM min<sup>-1</sup> and 12.5 μM respectively (Fig. 4). These results establish the capability of our late-stage lipidation method in synthesising a novel activity probe for LspPae.

In conclusion, a robust approach to late-stage peptide lipidation that combines Dha chemistry with mild, aqueous thiol-Michael addition has been developed. The protocol enables direct,




Fig. 3 Lipidation of model peptides with decane thiol.




Fig. 4 Kinetic assay substrate saturation plot for the hydrolysis of peptide **10** by LspPae. Data points represent mean values  $\pm$  SD ( $n = 3$ ).



chemoselective lipidation of peptides with the biologically important DAG lipid moiety to furnish functional peptides. The methodology is compatible with saturated, unsaturated and complex lipids as well as various peptide sequences. This method was employed for the synthesis of a novel FRET activity probe for the bacterial enzyme LspA, offering considerable potential for antibacterial drug discovery. The methodology is expected to find widespread application in furthering our understanding of bacterial lipoprotein biology and in the discovery of novel therapeutics.

This project was funded by the Irish Research Council project ID GOIPG/2020/312 and Science Foundation Ireland grants 19/FFP/6667 (E. M. S), 16/IA/4435 (M. C.), 22/FFP-A/10278 (M. C.), GOIPG/2020/312 (G. S.) and GOIPG/2023/3976 (M. R.)

## Data availability

The data supporting this article have been included as part of the ESI.†

## Conflicts of interest

There are no conflicts to declare.

## Notes and references

- 1 C. C. Hanna, J. Kriegesmann, L. J. Dowman, C. F. W. Becker and R. J. Payne, *Angew. Chem., Int. Ed.*, 2022, **61**, e202111266.
- 2 W. Ma, H. Liu and X. Li, *ChemBioChem*, 2023, **24**, e202300348.
- 3 T. Mejuch and H. Waldmann, *Bioconjugate Chem.*, 2016, **27**, 1771–1783.
- 4 R. D. Ballantine, K. Al Ayed, S. J. Bann, M. Hoekstra, N. I. Martin and S. A. Cochrane, *RSC Med. Chem.*, 2022, **13**, 1640–1643.
- 5 B. Ludolph, F. Eisele and H. Waldmann, *J. Am. Chem. Soc.*, 2002, **124**, 5954–5955.
- 6 J. M. Palomo, M. Lumbierres and H. Waldmann, *Angew. Chem., Int. Ed.*, 2006, **45**, 477–481.
- 7 A. D. de Araujo, H. T. Nguyen and D. P. Fairlie, *ChemBioChem*, 2021, **22**, 1784–1789.
- 8 L. Guo, C. Wang, J. Broos and O. P. Kuipers, *J. Biol. Chem.*, 2023, **299**, 104845.
- 9 S.-H. Yang, P. W. R. Harris, G. M. Williams and M. A. Brimble, *Eur. J. Org. Chem.*, 2016, 2608–2616.
- 10 Y. Zheng, Y. Cong, E. W. Schmidt and S. K. Nair, *Acc. Chem. Res.*, 2022, **55**, 1313–1323.
- 11 D. Kobayashi, E. Kuraoka, J. Hayashi, T. Yasuda, Y. Kohmura, M. Denda, N. Harada, N. Inagaki and A. Otaka, *ACS Med. Chem. Lett.*, 2022, **13**, 1125–1130.
- 12 N. Nischan, M. A. Kasper, T. Mathew and C. P. R. Hackenberger, *Org. Biomol. Chem.*, 2016, **14**, 7500–7508.
- 13 T. Schlatzer, J. Kriegesmann, H. Schroder, M. Trobe, C. Lembacher-Fadum, S. Santner, A. V. Kravchuk, C. F. W. Becker and R. Breinbauer, *J. Am. Chem. Soc.*, 2019, **141**, 14931–14937.
- 14 L. Smithers, S. Olatunji and M. Caffrey, *Front. Microbiol.*, 2021, **12**.
- 15 D. Ding, Y. Wen, C.-M. Liao, X.-G. Yin, R.-Y. Zhang, J. Wang, S.-H. Zhou, Z.-M. Zhang, Y.-K. Zou, X.-F. Gao, H.-W. Wei, G.-F. Yang and J. Guo, *J. Med. Chem.*, 2023, **66**, 1467–1483.
- 16 I. W. Hamley, *Bioconjugate Chem.*, 2021, **32**, 1472–1490.
- 17 S. Olatunji, X. Yu, J. Bailey, C.-Y. Huang, M. Zapotoczna, K. Bowen, M. Remškar, R. Müller, E. M. Scanlan, J. A. Geoghegan, V. Olieric and M. Caffrey, *Nat. Commun.*, 2020, **11**, 140.
- 18 S. Kitamura and D. W. Wolan, *FEBS Lett.*, 2018, **592**, 2289–2296.
- 19 S. Wang, K. Wu, Y.-J. Tang and H. Deng, *Nat. Prod. Rep.*, 2024, **41**, 273–297.
- 20 G. J. Bernardes, J. M. Chalker, J. C. Errey and B. G. Davis, *J. Am. Chem. Soc.*, 2008, **130**, 5052–5053.
- 21 T. H. Wright, B. J. Bower, J. M. Chalker, G. J. L. Bernardes, R. Wiewiora, W.-L. Ng, R. Raj, S. Faulkner, M. R. J. Vallée, A. Phanumartwath, O. D. Coleman, M.-L. Thézénas, M. Khan, S. R. G. Galan, L. Lercher, M. W. Schombs, S. Gerstberger, M. E. Palm-Espling, A. J. Baldwin, B. M. Kessler, T. D. W. Claridge, S. Mohammed and B. G. Davis, *Science*, 2016, **354**, aag1465.
- 22 B. Josephson, C. Fehl, P. G. Isenegger, S. Nadal, T. H. Wright, A. W. J. Poh, B. J. Bower, A. M. Giltrap, L. Chen, C. Batchelor-McAuley, G. Roper, O. Arisa, J. B. I. Sap, A. Kawamura, A. J. Baldwin, S. Mohammed, R. G. Compton, V. Gouverneur and B. G. Davis, *Nature*, 2020, **585**, 530–537.
- 23 R. Petracca, K. A. Bowen, L. McSweeney, S. O'Flaherty, V. Genna, B. Twamley, M. Devocelle and E. M. Scanlan, *Org. Lett.*, 2019, **21**, 3281–3285.
- 24 G. Bao, P. Wang, X. Guo, Y. Li, Z. He, X. Song, T. Yu, J. Xie and W. Sun, *Org. Lett.*, 2023, **25**, 8338–8343.
- 25 J. M. Chalker, S. B. Gunnoo, O. Boutureira, S. C. Gerstberger, M. Fernández-González, G. J. L. Bernardes, L. Griffin, H. Hailu, C. J. Schofield and B. G. Davis, *Chem. Sci.*, 2011, **2**, 1666–1676.
- 26 M. Kicsák, M. Bege, I. Bereczki, M. Csávás, M. Herczeg, Z. Kupihár, L. Kovács, A. Borbás and P. Herczegh, *Org. Biomol. Chem.*, 2016, **14**, 3190–3192.
- 27 S. Ingale, T. Buskas and G.-J. Boons, *Org. Lett.*, 2006, **8**, 5785–5788.
- 28 R. E. Stafford, T. Fanni and E. A. Dennis, *Biochemistry*, 1989, **28**, 5113–5120.
- 29 D. Berne, V. Ladmira, E. Leclerc and S. Caillol, *Polymers*, 2022, **14**, 4457.
- 30 Y. Jiang, R. Li, F. Ren, S. Yang and A. Shao, *Bioconjugate Chem.*, 2024, **35**, 72–79.
- 31 J. Dadová, S. R. G. Galan and B. G. Davis, *Curr. Opin. Chem. Biol.*, 2018, **46**, 71–81.

